COIOSDeep risk insights through multi-disciplinary research across the globe
text
Item new Peer-reviewed Added

Blood test used with the standard marker CA19-9 detected early-stage pancreatic cancer

A prospective study of 1,785 people across four countries reports that an exosome-based blood test, used with the standard marker CA19-9, detected early-stage pancreatic cancer with high sensitivity.

A prospective study tested PANXEON, an exosome-based blood biomarker, in 1,785 individuals recruited across four countries. The biomarker was assessed in combination with carbohydrate antigen 19-9. The combination achieved high sensitivity for the detection of early-stage pancreatic cancer.

Why it is interesting: Prospective evidence, across four countries, on detecting pancreatic cancer early from a blood sample.

Source
Nature Medicine, 16 September 2026
Type
Peer-reviewed article
Design
Prospective multi-centre biomarker validation study, 1,785 individuals across four countries
Verdict
New finding
Driver
Cancer

Other drivers in Health today